Company overview
Immunexpress develops molecular diagnostics for rapid sepsis detection by analyzing host immune response gene expression from whole blood. Their flagship product, SeptiCyte RAPID, is a fully automated cartridge compatible with the Biocartis Idylla platform, delivering results in about one hour to differentiate sepsis from non-infectious inflammation. This technology supports clinicians in early triage and treatment decisions, improving patient outcomes and reducing healthcare costs.
Immunexpress Home - Immunexpress is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing, Diagnostics & Testing partner serving United States & Americas. Core focus areas include sepsis diagnostics, septicyte rapid, host response testing, molecular diagnostics, immune response sepsis.
Industry categories: CDMO & Manufacturing, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Immunexpress Home - Immunexpress include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://immunexpress.com
- Categories
- CDMO & Manufacturing, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- sepsis diagnostics, septicyte rapid, host response testing, molecular diagnostics, immune response sepsis
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is SeptiCyte RAPID and how does it work?
- SeptiCyte RAPID is a cartridge-based RT-PCR test that quantifies host immune-response gene expression from whole blood to generate a sepsis likelihood score. It analyzes RNA from immune cells to detect systemic infection response faster than pathogen identification, providing results in about one hour on the Biocartis Idylla platform.
- What regulatory approvals does Immunexpress have?
- Immunexpress products like SeptiCyte RAPID have been validated through extensive clinical trials worldwide. Specific regulatory statuses such as FDA clearance or CE marking are not detailed in available information; contact Immunexpress for current approvals.
- Where does Immunexpress operate and serve geographies?
- Immunexpress is headquartered in Seattle, USA, with operations in Brisbane, Australia. Their technology targets global healthcare systems, with clinical validation from worldwide trials, supporting use in emergency departments and critical care settings internationally.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
